Determination of spin Hall effect and spin diffusion length of Pt from self-consistent fitting of damping enhancement and inverse spin-orbit torque measurements

Understanding the evolution of spin-orbit torque (SOT) with increasing heavy-metal thickness in ferromagnet/normal metal (FM/NM) bilayers is critical for the development of magnetic memory based on SOT. However, several experiments have revealed an apparent discrepancy between damping enhancement and damping-like SOT regarding their dependence on NM thickness. Here, using linewidth and phase-resolved amplitude analysis of vector network analyzer ferromagnetic resonance (VNA-FMR) measurements, we simultaneously extract damping enhancement and both field-like and damping-like inverse SOT in Ni$_{80}$Fe$_{20}$/Pt bilayers as a function of Pt thickness. By enforcing an interpretation of the data which satisfies Onsager reciprocity, we find that both the damping enhancement and damping-like inverse SOT can be described by a single spin diffusion length ($\approx$ 4 nm), and that we can separate the spin pumping and spin memory loss (SML) contributions to the total damping. This analysis indicates that less than 40% of the angular momentum pumped by FMR through the Ni$_{80}$Fe$_{20}$/Pt interface is transported as spin current into the Pt. On account of the SML and corresponding reduction in total spin current available for spin-charge transduction in the Pt, we determine the Pt spin Hall conductivity ($\sigma_\mathrm{SH} = (2.36 \pm 0.04)\times10^6 \Omega^{-1} \mathrm{m}^{-1}$) and bulk spin Hall angle ($\theta_\mathrm{SH}=0.387 \pm0.008$) to be larger than commonly-cited values. These results suggest that Pt can be an extremely useful source of SOT if the FM/NM interface can be engineered to minimize SML. Lastly, we find that self-consistent fitting of the damping and SOT data is best achieved by a model with Elliott-Yafet spin relaxation and extrinsic inverse spin Hall effect, such that both the spin diffusion length and spin Hall conductivity are proportional to the Pt charge conductivity

Determination of the effective detector area of an energy-dispersive X-ray spectrometer at the scanning electron microscope using experimental and theoretical X-ray emission yields

Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG geförderten) Allianz- bzw. Nationallizenz frei zugänglich.This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.A method is proposed to determine the effective detector area for energy-dispersive X-ray spectrometers (EDS). Nowadays, detectors are available for a wide range of nominal areas ranging from 10 up to 150 mm2. However, it remains in most cases unknown whether this nominal area coincides with the “net active sensor area” that should be given according to the related standard ISO 15632, or with any other area of the detector device. Moreover, the specific geometry of EDS installation may further reduce a given detector area. The proposed method can be applied to most scanning electron microscope/EDS configurations. The basic idea consists in a comparison of the measured count rate with the count rate resulting from known X-ray yields of copper, titanium, or silicon. The method was successfully tested on three detectors with known effective area and applied further to seven spectrometers from different manufacturers. In most cases the method gave an effective area smaller than the area given in the detector description

Die Crowd-Community als Lieferant auf der letzten Meile?

In der Last-Mile-Logistik werden zunehmend neue Trends diskutiert. Dazu zählen automatisierte Fahrzeuge, Drohnen oder auch emissionsfreie Zustellungen unter Einsatz von E-Fahrzeugen und (Lasten-)Rädern. Aber auch Crowd Delivery (oder auch Crowd Logistics) wird als neue Form der (urbanen) Logistik gehandelt (Botsman 2014, Kunze 2016). Crowd Delivery beschreibt unter anderem das Mitbringen (z. B. von Paketen oder Gegenstände aus Geschäften) durch Privatpersonen, die ohnehin gerade unterwegs sind, sich in dem Geschäft aufhalten oder sich als Bote etwas dazu verdienen möchten. Dadurch sollen Wege eingespart, Ressourcen geschont und Städte verkehrlich entlastet werden. Doch wie kommt man zu einer lokalen “Liefer-Crowd-Community” und wie lassen sich Personen dazu motivieren? Innerhalb eines Feldtests am Grazer Fesch’Markt soll aufgezeigt werden, wie eine Crowd-Community rekrutiert, aufgebaut und auf ihre Funktions- und Motivationslogiken beim „Mitnehmen” getestet werden kann. Es wird dabei bewusst auf Geldleistungen verzichtet, um die intrinsischen Motive wie Spaß und Neugier auf ihre Anreizwirkung auszuprobieren. Die Annahmme war unter anderem, dass bei dem Fesch’Markt mit 140 Ausstellern und etwa 10.000 Besuchern eine ausreichende Nutzerfrequenz sowie ein junges, Rad-affines Publikum vorzufinden ist

Swiss Corporate Sustainability Survey 2012 : Nachhaltigkeit in Schweizer Unternehmen

StudieDas Thema Nachhaltigkeit ist viel diskutiert und immer wieder Gegenstand von Untersuchungen. Der Erkenntnisgewinn der bereits existierenden Studien liegt grösstenteils in der Bedeutung von Nachhaltigkeit für Konsumenten, deren Kaufverhalten oder deren Verständnis des Begriffs Nachhaltigkeit. Wo aber steht der Werkplatz Schweiz bezüglich Nachhaltigkeit? Welche Herausforderungen sehen Unternehmen und wie wird Nachhaltigkeit in der Praxis umgesetzt? Die Studie "Swiss Corporate Sustainability Survey 2012" gibt Antwort auf diese und andere Fragen

Epidemiological situation of Lyme borreliosis in Belgium, 2003 to 2012.

BACKGROUND: Some studies show that the incidence of Lyme borreliosis is increasing in different European countries. In order to evaluate if this is also the case in Belgium, different data sources were consulted to describe the epidemiology of Lyme borreliosis in the country during the last decade. METHODS: Data from two databases were analyzed for the time period 2003-2010 and 2003-2012 for respectively: the registration of minimal clinical data from Belgian hospitals (principal and secondary diagnosis), and a sentinel laboratory network reporting positive laboratory results. RESULTS: The number of hospitalized cases per year remained stable between 2003 and 2010, ranging from 970 (in 2008) to 1453 (in 2006), with a median of 1132.5 cases per year. Between 2003 and 2012, yearly fluctuations in the number of positive tests were reported by the sentinel laboratory network (with a minimum of 996 positive tests in 2007 and a maximum of 1651 positive tests in 2005), but there is no increasing trend over the study period (median = 1200.5 positive tests per year). The highest incidence rates of hospitalization and the highest reported incidence of positive laboratory results are registered in the provinces of Luxemburg, Limburg, Flemish Brabant and Antwerp, with a typical seasonal pattern (peak in September). The age groups affected most are those from 5 to 14 years and 45 to 69. CONCLUSION: Based on hospital records and laboratory results, no increasing trend in Lyme disease was observed over the 2003-2012 period in Belgium. These results are in line with the stable incidence of erythema migrans reported by a sentinel network of general practitionners between 2003 and 2009. Multi-source surveillance of vector-borne diseases should be further implemented

Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer.

Functional redundancy shared by paralog genes may afford protection against genetic perturbations, but it can also result in genetic vulnerabilities due to mutual interdependency1-5. Here, we surveyed genome-scale short hairpin RNA and CRISPR screening data on hundreds of cancer cell lines and identified MAGOH and MAGOHB, core members of the splicing-dependent exon junction complex, as top-ranked paralog dependencies6-8. MAGOHB is the top gene dependency in cells with hemizygous MAGOH deletion, a pervasive genetic event that frequently occurs due to chromosome 1p loss. Inhibition of MAGOHB in a MAGOH-deleted context compromises viability by globally perturbing alternative splicing and RNA surveillance. Dependency on IPO13, an importin-β receptor that mediates nuclear import of the MAGOH/B-Y14 heterodimer9, is highly correlated with dependency on both MAGOH and MAGOHB. Both MAGOHB and IPO13 represent dependencies in murine xenografts with hemizygous MAGOH deletion. Our results identify MAGOH and MAGOHB as reciprocal paralog dependencies across cancer types and suggest a rationale for targeting the MAGOHB-IPO13 axis in cancers with chromosome 1p deletion

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND). a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Background: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease progression in secondary progressive multiple sclerosis, independent of relapses. Methods: ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year open-label extension (part 2). Enrolled patients aged 18–58 years were natalizumab-naive and had secondary progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, and Expanded Disability Status Scale (EDSS) scores of 3·0–6·5. In part 1, patients from 163 sites in 17 countries were randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients were stratified by site and by EDSS score (3·0–5·5 vs 6·0–6·5). Patients completing part 1 could enrol in part 2, in which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01416181. Findings: Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66–1·13; p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74–1·53; nominal p=0·753) or the T25FW (0·98, 0·74–1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT progression (OR 0·56, 95% CI 0·40–0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108–221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No progressive multifocal leukoencephalopathy occurred. Interpretation: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. Funding: Biogen